Clinical Trial Update: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating TQB2102 in combination with Behmosubaisumab and Payamprolizumab, with or without chemotherapy, for unresectable or metastatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Adenocarcinoma

Drugs mentioned

• Behmosubaisumab
• Payamprolizumab
• TQB2102

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: Gastroesophageal Adenocarcinoma | Phase 2 | Status: RECRUITING